Sankyo Company, Limited

Daiichi Sankyo Company, Limited

Hiroko Yoshida

Takeshi Takizawa

Kimihisa Ichikawa

Toshiaki Ohtsuka

Nobufusa Serizawa

Tatsuji Matsuoka

Yumi Matsui

Akiko Oguni

Tohru Takahashi

Jun Ohsumi

Hideyuki Haruyama

Akio Shiraishi

Shin Yonehara

Masahiko Ohtsuki

The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Anti-DR5 antibodies, polynucleotides and methods

Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.

Anti-Fas antibodies

A pharmaceutical composition containing an anti-human Fas antibody having apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, as active ingredients for the prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis. According to the present invention, the amount of the anti-Fas antibody to be used can be reduced and thereby the possibility that a patient may become tolerant to anti-Fas antibody as a result of the production of antibodies against the anti-Fas antibody in the patient's body or the like can be decreased, and thus is provided a pharmaceutical composition which can be used for a long time.

Pharmaceutical compositions containing anti-Fas antibody

Growing community of inventors

Tokyo, Japan

Hiroko Yoshida